{
  "trial_id": "NCT03701295",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, sex, race, ECOG performance status, total bilirubin, AST/ALT levels, creatinine levels, prior treatment history, presence of extramedullary disease, HIV status, HBV status, HCV status, presence of 11q23 rearrangement or partial tandem duplication, history of CNS disease, history of allergic reactions, use of medications affecting CYP3A4 or CYP450, use of medications affecting MATE1 and MATE2-K transporters, presence of uncontrolled intercurrent illness, pregnancy status, QT interval status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Ethnicity (NIH/OMB)",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "ECOG performance status",
        "total bilirubin",
        "AST/ALT levels",
        "creatinine levels",
        "prior treatment history",
        "presence of extramedullary disease",
        "HIV status",
        "HBV status",
        "HCV status",
        "presence of 11q23 rearrangement or partial tandem duplication",
        "history of CNS disease",
        "history of allergic reactions",
        "use of medications affecting CYP3A4 or CYP450",
        "use of medications affecting MATE1 and MATE2-K transporters",
        "presence of uncontrolled intercurrent illness",
        "pregnancy status",
        "QT interval status"
      ]
    },
    "processed-gen-response": "Age, sex, race, ECOG performance status, total bilirubin, AST/ALT levels, creatinine levels, prior treatment history, presence of extramedullary disease, HIV status, HBV status, HCV status, presence of 11q23 rearrangement or partial tandem duplication, history of CNS disease, history of allergic reactions, use of medications affecting CYP3A4 or CYP450, use of medications affecting MATE1 and MATE2-K transporters, presence of uncontrolled intercurrent illness, pregnancy status, QT interval status."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG Performance Status, Prothrombin Time (PT), Activated Partial Thromboplastin Time (aPTT), Total Bilirubin, Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Creatinine, Creatinine Clearance, HIV Status, Hepatitis B Status, Hepatitis C Status, Presence of Measurable Disease, Prior Treatment History, 11q23 Rearrangement Status, ",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Ethnicity (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "ECOG Performance Status",
        "Prothrombin Time (PT)",
        "Activated Partial Thromboplastin Time (aPTT)",
        "Total Bilirubin",
        "Aspartate Aminotransferase (AST)",
        "Alanine Aminotransferase (ALT)",
        "Creatinine",
        "Creatinine Clearance",
        "HIV Status",
        "Hepatitis B Status",
        "Hepatitis C Status",
        "Presence of Measurable Disease",
        "Prior Treatment History",
        "11q23 Rearrangement Status"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, ECOG Performance Status, Prothrombin Time (PT), Activated Partial Thromboplastin Time (aPTT), Total Bilirubin, Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Creatinine, Creatinine Clearance, HIV Status, Hepatitis B Status, Hepatitis C Status, Presence of Measurable Disease, Prior Treatment History, 11q23 Rearrangement Status"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG Performance Status, BMI, Creatinine Clearance, Total Bilirubin, AST, ALT, Prothrombin Time, aPTT, White Blood Cell Count, Hemoglobin, Platelet Count, Bone Marrow Blast Percentage, Peripheral Blood Blast Percentage, Extramedullary Disease Presence, Prior Treatment, HIV Status, Hepatitis B Status, Hepatitis C Status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Ethnicity (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "ECOG Performance Status",
        "BMI",
        "Creatinine Clearance",
        "Total Bilirubin",
        "AST",
        "ALT",
        "Prothrombin Time",
        "aPTT",
        "White Blood Cell Count",
        "Hemoglobin",
        "Platelet Count",
        "Bone Marrow Blast Percentage",
        "Peripheral Blood Blast Percentage",
        "Extramedullary Disease Presence",
        "Prior Treatment",
        "HIV Status",
        "Hepatitis B Status",
        "Hepatitis C Status"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, ECOG Performance Status, BMI, Creatinine Clearance, Total Bilirubin, AST, ALT, Prothrombin Time, aPTT, White Blood Cell Count, Hemoglobin, Platelet Count, Bone Marrow Blast Percentage, Peripheral Blood Blast Percentage, Extramedullary Disease Presence, Prior Treatment, HIV Status, Hepatitis B Status, Hepatitis C Status."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, ECOG performance status, Karnofsky performance score, weight, height, body mass index (BMI), prothrombin time (PT), activated partial thromboplastin time (aPTT), total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatinine, creatinine clearance, presence of measurable disease, type of 11q23 rearrangement or partial tandem duplication, prior treatment history, HIV status, hepatitis B virus (HBV) status, hepatitis C virus (HCV) status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ],
        [
          "ECOG performance status",
          "ECOG performance status"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "Karnofsky performance score",
        "weight",
        "height",
        "body mass index (BMI)",
        "prothrombin time (PT)",
        "activated partial thromboplastin time (aPTT)",
        "total bilirubin",
        "aspartate aminotransferase (AST)",
        "alanine aminotransferase (ALT)",
        "creatinine",
        "creatinine clearance",
        "presence of measurable disease",
        "type of 11q23 rearrangement or partial tandem duplication",
        "prior treatment history",
        "HIV status",
        "hepatitis B virus (HBV) status",
        "hepatitis C virus (HCV) status"
      ]
    },
    "processed-gen-response": "Age, sex, race, ethnicity, ECOG performance status, Karnofsky performance score, weight, height, body mass index (BMI), prothrombin time (PT), activated partial thromboplastin time (aPTT), total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatinine, creatinine clearance, presence of measurable disease, type of 11q23 rearrangement or partial tandem duplication, prior treatment history, HIV status, hepatitis B virus (HBV) status, hepatitis C virus (HCV) status."
  }
}